Journal of neurointerventional surgery · 2026
Predictors of enucleation after intra-arterial chemotherapy for retinoblastoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roy Joanna, El-Hajj Victor Gabriel, Attaseth Taweevat, Pan Annie, Musmar Basel, Fayek Fady Bassem, Kim Wi Jin, Tjoumakaris Stavropoula I, Gooch Reid, Rosenwasser Robert H, Alshahrani Rabab, Shields Carol L, Jabbour Pascal
Аннотация
BACKGROUND: Intra-arterial chemotherapy (IAC) has emerged as a minimally invasive treatment modality for globe salvage in patients with retinoblastoma (Rb). There is limited knowledge of the factors that influence rates of enucleation after IAC.
OBJECTIVE: Our study identifies predictors of enucleation among Rb patients receiving IAC.
METHODS: This was a retrospective study of Rb patients who received IAC between January 2010 and December 2024 at a single center in the United States. The primary outcome was enucleation at last follow-up.
RESULTS: Of 305 patients, 26.89% (n=82) underwent enucleation and 73.11% (n=223) did not. On multivariate analysis, factors associated with increased risk for enucleation were greatest basal diameter (OR 1.07, 95% CI 1.00 to 1.15, p=0.035), bilateral Rb (OR 2.82, 95% CI 1.36 to 5.81, p=0.005), and advanced-stage disease at presentation (OR 7.45, 95% CI 1.92 to 28.9, p=0.004). The use of combination chemotherapy was associated with lower odds for enucleation compared with single-agent chemotherapy (OR 0.29, 95% CI 0.11 to 0.80, p=0.016), whereas double-agent chemotherapy was not significantly associated with enucleation (OR 0.90, 95% CI 0.46 to 1.75, p=0.75).
CONCLUSIONS: Larger tumors, bilateral disease, and advanced-stage disease were linked to higher odds of enucleation, whereas combination chemotherapy was associated with lower odds compared with single-agent chemotherapy. Future studies could help validate these results.
OBJECTIVE: Our study identifies predictors of enucleation among Rb patients receiving IAC.
METHODS: This was a retrospective study of Rb patients who received IAC between January 2010 and December 2024 at a single center in the United States. The primary outcome was enucleation at last follow-up.
RESULTS: Of 305 patients, 26.89% (n=82) underwent enucleation and 73.11% (n=223) did not. On multivariate analysis, factors associated with increased risk for enucleation were greatest basal diameter (OR 1.07, 95% CI 1.00 to 1.15, p=0.035), bilateral Rb (OR 2.82, 95% CI 1.36 to 5.81, p=0.005), and advanced-stage disease at presentation (OR 7.45, 95% CI 1.92 to 28.9, p=0.004). The use of combination chemotherapy was associated with lower odds for enucleation compared with single-agent chemotherapy (OR 0.29, 95% CI 0.11 to 0.80, p=0.016), whereas double-agent chemotherapy was not significantly associated with enucleation (OR 0.90, 95% CI 0.46 to 1.75, p=0.75).
CONCLUSIONS: Larger tumors, bilateral disease, and advanced-stage disease were linked to higher odds of enucleation, whereas combination chemotherapy was associated with lower odds compared with single-agent chemotherapy. Future studies could help validate these results.